An overview of pancreatic beta-cell defects in human type 2 diabetes: Implications for treatment

Regulatory Peptides

Volumn 146, Issue 1-3, 2008, Pages 4-11

  Marchetti, Piero ^a   Dotta, Francesco ^b   Lauro, Davide ^c   Purrello, Francesco ^d  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Apoptosis; Insulin secretion; Pancreatic beta cell; Type 2 diabetes

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; MESSENGER RNA; METFORMIN; PROTEIN BCL 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

APOPTOSIS; CELL SURVIVAL; GENOTYPE; HUMAN; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LANGERHANS CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CELL COUNT; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; METFORMIN;

EID: 38149042694     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.08.017     Document Type: Review

References (65)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 29 suppl 1 (2006) S43:48
2. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
3. American Diabetes Association. Classification of diabetes. Diabetes. Vital Statistics (2001) 5-8
4. American Diabetes Association. Mortality. Diabetes. Vital Statistics (2001) 75-86
5. Hogan P., Dall T., and Nikolov P. Diabetes: economic costs of diabetes in the U.S. in 2002. Diabetes Care 26 (2003) 917-932
6. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 24 (1998) 296-309
7. Kahn S.E. The relative contribution of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46 (2003) 3-19
8. Ferrannini E., and Mari A. Beta-cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47 (2004) 943-956
9. Buchanan T.A. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 25 suppl B (2003) 32-46
10. Levy J., Atkinson A.B., Bell P.M., et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15 (1998) 290-296
11. Rhodes C.J. Type 2 diabetes - a matter of beta-cell life and death?. Science 307 (2005) 380-384
12. Halban P.A. Cellular sources of new pancreatic beta-cells and therapeutic implications for regenerative medicine. Nat Cell Bio 6 (2004) 1021-1025
13. Dor Y., Brown J., Martinez O.I., et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429 (2004) 41-46
14. Bonner-Weir S., and Weir G.C. New sources of pancreatic beta-cells. Nat Biotechnol 23 (2005) 857-861
15. Donath M.Y., and Halban P.A. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47 (2004) 581-589
16. Westermark P., and Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15 (1978) 417-421
17. Saito K., Iwama N., and Takahashi T. Morphometrical analysis on topographical difference in size distribution, number and volume of islets in the human pancreas. Tohoku J Exp Med 124 (1978) 177-186
18. Gepts W., and Lecompte P.M. The pancreatic islets in diabetes. Am J Med 70 (1981) 105-115
19. Sakuraba H., Mizukami H., Yagihashi N., Wada R., Hanyu C., and Yagihashi S. Reduced beta cell mass and expression of oxidative stress related DNA damage in the islets of Japanese type 2 diabetic patients. Diabetologia 45 (2002) 85-96
20. Yoon K.H., Ko S.H., Cho J.H., et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes in Korea. J Clin Endocrinol Metab 88 (2003) 2300-2308
21. Butler A.E., Janson J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
22. Marchetti P., Del Guerra S., Marselli L., et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89 (2004) 5535-5541
23. Del Guerra S., Lupi R., Marselli L., et al. Functional and molecular alterations of pancreatic islets in human Type 2 diabetes. Diabetes 54 (2005) 727-735
24. Malaisse W.J. Physiology, pathology and pharmacology of insulin secretion: recent acquisitions. Diabetes Metab 23 suppl 3 (1997) 6-15
25. Henquin J.C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49 (2000) 1751-1760
26. Del Prato S., Marchetti P., and Bonadonna R.C. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 51 suppl 1 (2002) S109-S116
27. Marchetti P., Scharp D.W., McLear M., et al. Pulsatile insulin secretion from isolated human pancreatic islets. Diabetes 43 (1994) 827-830
28. Marchetti P., Del Prato S., Lupi R., et al. The pancreatic beta-cell in human type 2 diabetes. Nutr Metab Cardiovasc Dis 16 suppl 1 (2006) S3-S6
29. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
30. Porksen N. The in vivo regulation of pulsatile insulin secretion. Diabetologia 45 (2002) 3-20
31. Schmitz O., Brock B., Hollingdal M., Juhl C.B., and Porksen N. High frequency insulin pulsatility and type 2 diabetes: from phusiology and pathophysiology to clinical pharmacology. Diabetes Metab 28 suppl 9 (2002) 9-14
32. Lin J.M., Febregat M.E., Gomis R., et al. Pulsatile insulin release from islets isolated from three subjects with type 2 diabetes. Diabetes 51 (2002) 988-993
33. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Horm Metab Res 36 (2004) 775-781
34. Cerasi E., Nesher R., Gadot M., Gross D., and Kaiser N. Insulin secretion in obese and non obese NIDDM. Diabetes Res Clin Pract 28 (1995) S27-S37
35. Trajkovski M., Mziaut H., Schwarz P.E., and Solimena M. Genes of type 2 diabetes in beta cells. Endocrinol Metab Clin North Am 35 (2006) 357-369
36. Bell G.I., and Polonski K.S. Diabetes mellitus and genetically programmed defects in beta cell function. Nature 41 (2001) 788-791
37. Sladek R., Rocheleau G., Rung J., et al. A genome wide association study identifies novel risk loci for type 2 diabetes. Nature 445 (2007) 881-885
38. Lindgren C.M., Mahtani M.M., Widen E., et al. Genome wide search for type 2 diabetes mellitus susceptibility loci in Finnish families: the Botnia study. Am J Hum Genet 70 (2002) 509-516
39. Marchetti P., Lupi R., Federici M., et al. Insulin secretory function is impaired in isolated human islets carrying the gly972 arg IRS-1 polymorphism. Diabetes 51 (2002) 1419-1424
40. Patane G., Anello M., Piro S., Vigneri R., Purrello F., and Rabuazzo A.M. Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. Diabetes 51 (2002) 2749-2756
41. Poitout V., and Robertson R.P. Minireview: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endcorinology 143 (2002) 339-342
42. Unger R.H. Lipotoxic diseases. Annu Rev Med 53 (2002) 319-336
43. Prentki M., and Nolan C.J. Islet beta cell failure in type 2 diabetes. J Clin Invest 116 (2006) 1802-1812
44. Cnop M., Welsh N., Jonas J.C., Jorns A., Lenzen S., and Eizirik D.L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 suppl 2 (2005) 97-107
45. Andreozzi F., D'Alessandris C., Federici M., et al. Activation of the hexosamine pathway leads to phosphorylation of IRS-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mTOR insulin biosynthetic pathway in RIN pancreatic beta-cells. Endocrinology 145 (2004) 2845-2857
46. Lupi R., Dotta F., Marselli L., et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51 (2002) 1437-1442
47. Hoppener J.W.M., and Lips C.J.M. Role of amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol 38 (2006) 726-736
48. Ritzel R.A., Meier J.J., Lin C.Y., Veldhuis J.D., and Butler P.C. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56 (2007) 65-71
49. Westermark P., Wernstedt C., Wilander E., et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuopeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84 (1987) 3881-3885
50. Cooper G.J.S., Willis A.C., Clark A., et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84 (1987) 8628-8632
51. Ritzel R.A., and Butler P.C. Replication increases beta cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52 (2003) 1701-1708
52. Meier J.J., Kayed R., Lin C.Y., et al. Inhibition of human UAPP fibril formation does not prevent beta cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab 291 (2006) E1317-E1324
53. Ehes J.A., Perren A., Eppler E., et al. Increased number of islet associated macrophages in type 2 diabetes. Diabetes (Jun 19 2007) (Epub ahead of print)
54. Donath M.Y., Ehes J.A., Schulthess F., et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54 suppl 2 (2005) s108-s113
55. Welsh N., Cnop M., Kharroubi I., Bugliani M., Lupi R., Marchetti P., and Eizirik D.L. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?. Diabetes 54 (2005) 3238-3244
56. Fernandez-Alvarez J., Conget I., Rasschaert J., et al. Enzymatic, metabolic and secretory patterns in human islets of type 2 (non-insulin-dependent) diabetic patients. Diabetologia 37 (1994) 177-181
57. Deng S., Vatamaniuk M., Huang X., et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53 (2004) 624-632
58. Anello M., Lupi R., Spampinato D., et al. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 48 (2005) 282-289
59. Ostenson C.G., Gaisano H., Sheu L., Tibell A., and Bartfai T. Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients. Diabetes 55 (2006) 435-440
60. Lupi R., Del Guerra S., Tellini C., Giannarelli R., Coppelli A., Lorenzetti M., Carmellini M., Mosca F., Navalesi R., and Marchetti P. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 364 (1999) 205-209
61. Lupi R., Del Guerra S., Fierabracci V., Marselli L., Novelli M., Patane G., Boggi U., Mosca F., Piro S., Del Prato S., and Marchetti P. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 51 Suppl 1 (2002) S134-S137
62. Lupi R., Del Guerra S., Marselli L., Bugliani M., Boggi U., Mosca F., Marchetti P., and Del Prato S. Rosiglitazone prevents the impairment of human islet function induced by fatty-acids. Evidence for a role PPAR-{gamma}2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 286 (2004) E560-E567
63. Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 128 (2005) 149-157
64. Drucker D.J., and Nauck M.A. The incretin system: glucagon like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
65. Lupi R, Mancarella R, Del Guerra S, Bugliani M, Del Prato S, Boggi U, Filipponi F, Torri S, D'Aleo V, Marchetti P., submitted for publication. Effects of exendin-4 on human type 2 diabetes islets.